Mifepristone Still Showing Positive Results for Treatment of Central Serous Chorioretinopathy

For the past 18 years, reports have been published here on the slow progress of research for treatment of central serous chorioretinopathy (CSC). Sometimes misdiagnosed as early-onset age-related macular degeneration, CSC is a disease of the central retina (the macula) affecting mostly middle-aged males, and it is thought to be caused by over-production of stress [Read More]

Abicipar for Wet AMD May Extend Time Between Treatments

Allergan and Molecular Partners have announced the release of two positive clinical trials of a new treatment for wet age-related macular degeneration (wAMD). The trials, named SEQUOIA and CEDAR, demonstrated that the biological drug Abicipar is equal to Genentech’s Lucentis (ranibizumab), with the added benefit that Abicipar treatments are effective at up to 12-week dosages. [Read More]

Müller Cells Might Be Re-programmed to Become Sight Cells

Degeneration of photoreceptors (rod and cone cells) is a leading cause of vision loss. Since there are no effective treatments to restore vision once photoreceptors are lost, photoreceptor regeneration has the very real prospect of alleviating blindness in these eyes. To that end, a recent innovative study has demonstrated the possibility of reprogramming Müller glial [Read More]

Mediterranean Diet Lowers Risk of AMD

Studies in France and the Netherlands have shown that a Mediterranean diet is linked to a lower risk of age-related macular degeneration (AMD). Researchers investigated the effects of such a diet on a large sample from subjects from two population-based prospective studies. The diet consists of more than median intakes of vegetables, fruits, legumes, cereals, [Read More]